FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma

首页 > 成果 > 详情

认领

导出

Link by DOI

反馈

作者信息关键词期刊信息基础信息归属信息摘要

成果类型：

期刊论文

作者：

Tan, Xiang-Peng;Xiong, Ben-Han;Zhang, Yuan-Xu;Wang, Shen-Li;Zuo, Qian;...

作者机构：

[Tan, Xiang-Peng] Jinan Univ, Affiliated Hosp 1, Guangzhou, Peoples R China.

[Li, Jing] Hunan Univ Chinese Med, Hosp 1, Changsha, Peoples R China.

[Zhang, Yuan-Xu; Xiong, Ben-Han] Jinan Univ, Coll Life Sci & Technol, Guangzhou, Peoples R China.

[Zuo, Qian] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Breast Dis, Guangzhou, Peoples R China.

[Wang, Shen-Li] Jinan Univ, Biomed Translat Res Inst, Guangzhou, Peoples R China.

语种：

英文

关键词：

Akt/mTOR signaling pathway;FXYD5;HCC;Sorafenib resistance

期刊：

European Journal of Pharmacology

ISSN：

0014-2999

年：

2022

卷：

931

页码：

175186

DOI：

10.1016/j.ejphar.2022.175186

基金类别：

Youth Project of Education Department of Hunan Province [21B0365]; General Project of Hunan Health Commission [20200949]; Changsha Natural Science Foundation [KQ2202453]

机构署名：

本校为其他机构

院系归属：

第一中医临床学院

摘要：

Tumor chemoresistance is often a major cause for the failure of chemotherapy. The resistance of hepatocellular carcinoma (HCC) cells to sorafenib significantly limits its therapeutic effect in HCC patients. For the first time, we found that FXYD domain-containing ion transport regulator 5 (FXYD5) is highly expressed in sorafenib-resistant HCC cells. In addition, the protein expression level of FXYD5 was markedly higher in HCC tissues than in paracancerous tissues. Remarkably, downregulation of FXYD5 expression in Huh7/sora cells reversed their resistance to sorafenib. Moreover, overexpression ...

反馈

产权有误：本人成果被他人认领

数据有误：数据基本信息有误

归属有误：成果的院系归属、机构署名归属有误

其他原因：

验证码：

看不清楚，换一个

确定

取消

成果认领

标题：

用户	作者	通讯作者	--
	请选择	请选择	--

确定

取消

FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma

反馈

成果认领

提示

该栏目需要登录且有访问权限才可以访问